Latest News

  • Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical...
  • High yield at high selectivity – lentiviral vectors with Nipah envelope proteins developed

    Langen, 09.06.2016. To transfer genes exclusively into the patient’s therapy relevant cells is in the focus of current research approaches in gene therapy. Researchers of the Paul-Ehrlich-Institut have succeeded in modifying envelope proteins of Nipah virus (NiV) and to combine them with lentiviruses in such a way that they can now be used for a...
  • TrakCel selected for EU CAR-T Project

    Cardiff, UK – TrakCel Ltd., a leading provider of Clinical supply chain orchestration technology for cell, gene and immunotherapies, today announces its selection as a key partner in CARAT, an EU-funded project to support the development of CAR T-cell therapies. The CARAT (Chimeric Antigen Receptors (CARs) for Advanced Therapies) project aims to...
  • Miltenyi Biotech coordinates EU-funded project to develop innovative cell manufacturing platform

    Cancer is highlighted by the WHO as one of the leading causes of mortality and morbidity. For instance, in Europe alone, more than 50,000 people die of leukaemia every year. In response to this major health issue Miltenyi Biotec coordinates the new EU-funded project CARAT taking on the mission to deliver new methods to enable the wide use of novel...

Upcoming Events